Literature DB >> 9267303

Clenched-fist injury complicated by methicillin-resistant Staphylococcus aureus.

G Berlet1, R S Richards, J H Roth.   

Abstract

Hand infections are a common sequela of clenched-fist injuries. The majority of these infections are due to Staphylococcus and Streptococcus species. Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly being isolated in Canadian health care facilities. In addition, MRSA now needs to be considered in community acquired hand infections that fail to respond to common empiric therapy. A 51-year-old man with MRSA due to a hand injury was treated successfully with vancomycin. The prevalence, mechanism of resistance and treatment of MRSA are briefly reviewed.

Entities:  

Mesh:

Year:  1997        PMID: 9267303      PMCID: PMC3949941     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  5 in total

1.  Fighting never pays.

Authors:  R Usatine
Journal:  West J Med       Date:  2000-07

2.  A retrospective analysis of practice patterns in the treatment of methicillin-resistant Staphylococcus aureus skin and soft tissue infections at three Canadian tertiary care centres.

Authors:  John M Conly; H Grant Stiver; Karl A Weiss; Debbie L Becker; Andrew J Rosner; Elizabeth Miller
Journal:  Can J Infect Dis       Date:  2003-11

Review 3.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Is methicillin-resistant Staphylococcus aureus an emerging community pathogen? A review of the literature.

Authors:  M A Gardam
Journal:  Can J Infect Dis       Date:  2000-07

5.  The costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in Canada.

Authors:  Andrew J Rosner; Debbie L Becker; Angelina H Wong; Elizabeth Miller; John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.